QSAR model for CYP450 2C9 inhibitor (v1.0)



ProtoADME

ProtoADME is a computational (in silico) tool focused on the prediction of endpoints related with the ADME (Absortion, Distribution, Metabolism and Excretion) of chemical substances.

Endpoint

Toxicokinetic: CYP450 2C9 inhibitor

The microsomal cytochrome P450 (CYP) family 4 monooxygenases are the major fatty acid omega-hydroxylases. These enzymes remove excess free fatty acids to prevent lipotoxicity, catabolize leukotrienes and prostanoids, and also produce bioactive metabolites from arachidonic acid omega-hydroxylation. In addition to endogenous substrates, recent evidence indicates that CYP4 monooxygenases can also metabolize xenobiotics, including therapeutic drugs. If a compound is a CYP inhibitor may decrease the metabolism of comedicated drugs.

Metrics

Training set

Experimental values	QSAR predictions		
	Non-inhibitor	Inhibitor	
Non-inhibitor	228	28	
Inhibitor	35	202	

V	′a	lid	la	tic	on	S	et

QSAR predictions			
Non-inhibitor	Inhibitor		
63	31		
26	46		
	Non-inhibitor		


Parameters	Training	Validation
Accuracy	0.87	0.66
Sensitivity / recall	0.85	0.64
Specificity	0.89	0.67
Precision	0.88	0.60
Negative predictive value	0.87	0.71
F-score	0.87	0.62
Matthews Correlation Coefficient	0.74	0.31
Critical Success Index	0.76	0.45
Area under the ROC	0.87	0.65

ProtoADME is part of



ProtoPRED platform allows the easy, fast and user-friendly prediction of different properties of chemical compounds, using proprietary (Q)SAR models







protopred@protoqsar.com